Exchange Traded Concepts LLC Acquires 1,164 Shares of United Therapeutics Corporation $UTHR

Exchange Traded Concepts LLC lifted its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 31.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,864 shares of the biotechnology company’s stock after purchasing an additional 1,164 shares during the quarter. Exchange Traded Concepts LLC’s holdings in United Therapeutics were worth $2,370,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of UTHR. AE Wealth Management LLC boosted its holdings in United Therapeutics by 396.3% in the third quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock worth $1,798,000 after purchasing an additional 3,424 shares in the last quarter. Great Lakes Advisors LLC increased its position in United Therapeutics by 194.7% during the third quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock worth $1,888,000 after buying an additional 2,975 shares during the last quarter. Optimize Financial Inc bought a new position in United Therapeutics during the third quarter valued at about $444,000. Simplify Asset Management Inc. acquired a new stake in shares of United Therapeutics in the third quarter worth about $8,351,000. Finally, Osaic Holdings Inc. lifted its position in shares of United Therapeutics by 271.0% in the second quarter. Osaic Holdings Inc. now owns 46,082 shares of the biotechnology company’s stock worth $14,027,000 after buying an additional 33,662 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $592.98 on Wednesday. The company has a market cap of $25.99 billion, a P/E ratio of 21.25, a P/E/G ratio of 2.12 and a beta of 0.84. The stock’s 50-day moving average is $500.92 and its 200-day moving average is $476.29. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $607.89.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. During the same period in the previous year, the company posted $6.19 earnings per share. The firm’s revenue for the quarter was up 7.4% on a year-over-year basis. As a group, equities analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $489.91, for a total value of $4,654,145.00. Following the sale, the chief executive officer owned 130 shares in the company, valued at approximately $63,688.30. This trade represents a 98.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the completion of the sale, the chief financial officer owned 18,876 shares in the company, valued at approximately $9,956,712.48. The trade was a 34.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 333,820 shares of company stock valued at $165,495,478 in the last three months. Company insiders own 10.30% of the company’s stock.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: TETON‑1 Phase 3 success — The pivotal TETON‑1 study met its primary endpoint, showing a clinically meaningful FVC improvement (Hodges‑Lehmann estimate ~130.1 mL vs placebo at 52 weeks), supporting Tyvaso’s potential expansion into IPF and a likely regulatory path. BusinessWire: TETON‑1 Results
• Positive Sentiment: Wall Street upgrades and target lifts — Multiple firms raised price targets (TD Cowen, HC Wainwright, BofA, TD Cowen to ~$660 among others), reflecting materially higher revenue/market‑expansion assumptions if Tyvaso wins an IPF label. TickerReport: HC Wainwright Raise
• Positive Sentiment: Buyback / ASR and ralinepag momentum — Recent company buyback authorizations (including accelerated share repurchase activity) and positive Phase 3 ralinepag data (PAH) add to near‑term shareholder‑return dynamics and reduce share count risk. QuiverQuant: Buyback & Ralinepag
• Neutral Sentiment: Heavy call‑option activity and volume — Unusually large call buying and above‑average equity volume indicate speculative positioning and short covering; this can amplify moves short term but is not a fundamental read‑through by itself.
• Neutral Sentiment: Mixed analyst stances — Some firms raised targets but kept neutral/equal‑weight ratings (e.g., Wells Fargo, BofA), signaling differing views on how much IPF uptake and pricing convert to durable earnings. 24/7 Wall St.: Dual Target Hikes
• Negative Sentiment: Valuation and execution risk cautions — Some analysts note that strong trial momentum is partially offset by high valuation and execution/regulatory risk (commercial rollout, payer uptake), which could limit further multiple expansion. TipRanks: Balanced View
• Negative Sentiment: Large insider selling flagged — Public filings compiled by data providers show extensive insider sales over recent months; investors often view concentrated insider selling as a negative signal to monitor. QuiverQuant: Insider Activity
• Negative Sentiment: Questions about sustainability of the move — Some market commentaries (and earnings‑estimate trends) warn the post‑trial pop may not sustain unless follow‑on commercialization, label, and payer access dynamics become clearer. Zacks: Will Strength Last?

Wall Street Analyst Weigh In

A number of research analysts have recently commented on UTHR shares. UBS Group increased their price objective on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Wells Fargo & Company boosted their target price on United Therapeutics from $486.00 to $575.00 and gave the stock an “equal weight” rating in a report on Tuesday. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Bank of America increased their price target on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a report on Tuesday. Finally, Royal Bank Of Canada lifted their price target on shares of United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $586.00.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.